• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

甲泼尼龙治疗高危普通型 COVID-19 肺炎患者的疗效：一项回顾性队列研究。

Effectiveness of methylprednisolone therapy in patients with a high-risk common type of COVID-19 pneumonia: a retrospective cohort study.

机构信息

Department of Respiratory Medicine, The First Affiliated Hospital of Hainan Medical University, Haikou, China.

Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

出版信息

Clin Exp Med. 2022 Aug;22(3):487-497. doi: 10.1007/s10238-021-00765-1. Epub 2021 Oct 22.

DOI:10.1007/s10238-021-00765-1
PMID:34677701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8532093/
Abstract

The optimal timing of glucocorticoid treatment for coronavirus disease 2019 (COVID-19) pneumonia is uncertain. We evaluated the clinical outcomes of methylprednisolone therapy (MPT) for patients with a high-risk common type (HRCT) COVID-19 pneumonia. We conducted a multicenter retrospective cohort study in Northeast China. A comparison was performed between the standard treatment (SDT) group and the SDT + MPT group to determine the efficacy of methylprednisolone in treating HRCT COVID-19 pneumonia. We collected the medical records of 403 patients with HRCT COVID-19 pneumonia (127 in the SDT + MPT group and 276 in the SDT group). None of the patients had received mechanical ventilation or died. Furthermore, there were no side effects associated with MPT. Patients in the SDT + MPT group treated with methylprednisolone received an intravenous injection for a median interval of five days (interquartile range of 3 to 7 days). The trends in lymphocyte count, C-reactive protein, interleukin 6, lactic acid dehydrogenase, respiratory rate, SpO2, PaO2, D-dimer and body temperature were similar between the SDT + MPT and SDT groups. The results for the SDT + MPT group seemed to improve faster than those for the SDT group; however, the results were not statistically significant. Clinical outcomes revealed that the average hospitalized days and the rate of progression to severe type COVID-19 pneumonia in both the SDT + MPT group and the SDT group were 14.56 ± 0.57 days versus 16.55 ± 0.3 days (p = 0.0009) and 21.26% (27/127) versus 32.4% (89/276) (p = 0.0247), respectively. The 16-day nucleic acid negative rate was higher in the SDT + MPT group than in the SDT group, 81.73% (104/127) versus 65.27% (180/276) (p = 0.0006). MPT effectively prevents patients with HRCT COVID-19 pneumonia from progressing to the severe stage.

摘要

糖皮质激素治疗 2019 冠状病毒病（COVID-19）肺炎的最佳时机尚不确定。我们评估了甲基强的松龙治疗（MPT）高危普通型（HRCT）COVID-19 肺炎患者的临床结局。我们在中国东北地区进行了一项多中心回顾性队列研究。将标准治疗（SDT）组与 SDT+MPT 组进行比较，以确定甲基强的松龙治疗 HRCT COVID-19 肺炎的疗效。我们收集了 403 例 HRCT COVID-19 肺炎患者（SDT+MPT 组 127 例，SDT 组 276 例）的病历。没有患者接受机械通气或死亡。此外，MPT 无副作用。接受甲基强的松龙治疗的 SDT+MPT 组患者静脉注射中位数间隔为 5 天（四分位距 3 至 7 天）。SDT+MPT 组和 SDT 组的淋巴细胞计数、C 反应蛋白、白细胞介素 6、乳酸脱氢酶、呼吸频率、SpO2、PaO2、D-二聚体和体温趋势相似。SDT+MPT 组的结果似乎比 SDT 组改善更快，但差异无统计学意义。临床结果表明，SDT+MPT 组和 SDT 组的平均住院天数和进展为重型 COVID-19 肺炎的发生率分别为 14.56±0.57 天与 16.55±0.3 天（p=0.0009）和 21.26%（27/127）与 32.4%（89/276）（p=0.0247）。SDT+MPT 组 16 天核酸转阴率高于 SDT 组，81.73%（104/127）与 65.27%（180/276）（p=0.0006）。MPT 可有效防止 HRCT COVID-19 肺炎患者进展为重症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/2697f694dcdd/10238_2021_765_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/110d701e16f9/10238_2021_765_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/525950767c59/10238_2021_765_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/f39ae23ff839/10238_2021_765_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/ad2301f7eeca/10238_2021_765_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/3a50183c18e2/10238_2021_765_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/2697f694dcdd/10238_2021_765_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/110d701e16f9/10238_2021_765_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/525950767c59/10238_2021_765_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/f39ae23ff839/10238_2021_765_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/ad2301f7eeca/10238_2021_765_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/3a50183c18e2/10238_2021_765_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86a7/8532093/2697f694dcdd/10238_2021_765_Fig6_HTML.jpg

相似文献

1
Effectiveness of methylprednisolone therapy in patients with a high-risk common type of COVID-19 pneumonia: a retrospective cohort study.甲泼尼龙治疗高危普通型 COVID-19 肺炎患者的疗效：一项回顾性队列研究。
Clin Exp Med. 2022 Aug;22(3):487-497. doi: 10.1007/s10238-021-00765-1. Epub 2021 Oct 22.
2
Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.COVID-19 肺炎的糖皮质激素（CORTIVID）治疗：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):43. doi: 10.1186/s13063-020-04999-4.
3
Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.地塞米松与甲泼尼龙大剂量治疗新冠肺炎肺炎。
PLoS One. 2021 May 25;16(5):e0252057. doi: 10.1371/journal.pone.0252057. eCollection 2021.
4
Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial.早期使用皮质类固醇可能会延长 COVID-19 肺炎非重症监护病房患者的 SARS-CoV-2 脱落：一项多中心、单盲、随机对照试验。
Respiration. 2021;100(2):116-126. doi: 10.1159/000512063. Epub 2021 Jan 22.
5
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.阿那白滞素联合甲泼尼龙治疗重症 COVID-19 肺炎和炎症过度激活患者：一项观察性队列研究。
J Allergy Clin Immunol. 2021 Feb;147(2):561-566.e4. doi: 10.1016/j.jaci.2020.11.006. Epub 2020 Nov 19.
6
Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.沙利鲁单抗对比标准治疗用于住院 COVID-19 肺炎患者的早期治疗：SARTRE：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 16;21(1):794. doi: 10.1186/s13063-020-04633-3.
7
Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit.比较 ICU 中 COVID-19 肺炎患者的脉冲剂量和高剂量皮质类固醇与无皮质类固醇治疗。
J Med Virol. 2022 Jan;94(1):349-356. doi: 10.1002/jmv.27351. Epub 2021 Sep 28.
8
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
9
Prolonged higher dose methylprednisolone conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS).COVID-19 肺炎中较长时间的高剂量甲泼尼龙与常规地塞米松的随机对照试验（MEDEAS）。
Eur Respir J. 2023 Apr 20;61(4). doi: 10.1183/13993003.01514-2022. Print 2023 Apr.
10
Effects of different doses of methylprednisolone on clinical outcomes in patients with severe community-acquired pneumonia: a study protocol for a randomized controlled trial.不同剂量甲泼尼龙治疗重症社区获得性肺炎患者的临床结局影响：一项随机对照试验研究方案。
Trials. 2022 May 21;23(1):423. doi: 10.1186/s13063-022-06404-8.

本文引用的文献

1
Emergence of a non vaccine-cognate enterovirus A71 genotype C1 in mainland China.中国大陆出现非疫苗相关肠道病毒 A71 基因型 C1。
J Infect. 2021 Mar;82(3):407-413. doi: 10.1016/j.jinf.2020.12.020. Epub 2020 Dec 26.
2
Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis.糖皮质激素治疗 2019 冠状病毒病相关急性呼吸窘迫综合征：一项倾向评分分析的队列研究。
Crit Care. 2020 Nov 10;24(1):643. doi: 10.1186/s13054-020-03340-4.
3
Early Noninvasive Cardiac Testing After Emergency Department Evaluation for Suspected Acute Coronary Syndrome.
疑似急性冠脉综合征患者在急诊科评估后进行早期无创性心脏检查。
JAMA Intern Med. 2020 Dec 1;180(12):1621-1629. doi: 10.1001/jamainternmed.2020.4325.
4
Corticosteroids as adjunctive therapy in the treatment of coronavirus disease 2019: A report of two cases and literature review.皮质类固醇作为辅助治疗 2019 冠状病毒病：两例报告及文献复习。
J Infect Chemother. 2021 Jan;27(1):94-98. doi: 10.1016/j.jiac.2020.09.007. Epub 2020 Sep 9.
5
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.糖皮质激素治疗住院严重 COVID-19 患者的疗效：一项多中心研究。
Clin Microbiol Infect. 2021 Jan;27(1):105-111. doi: 10.1016/j.cmi.2020.09.014. Epub 2020 Sep 22.
6
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.静脉注射甲泼尼龙脉冲治疗住院的严重 COVID-19 患者：一项随机对照临床试验的结果。
Eur Respir J. 2020 Dec 24;56(6). doi: 10.1183/13993003.02808-2020. Print 2020 Dec.
7
Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19:Serologic Testing.美国传染病学会关于新冠病毒病诊断的指南：血清学检测
Clin Infect Dis. 2020 Sep 12. doi: 10.1093/cid/ciaa1343.
8
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.地塞米松对中重度 COVID-19 相关急性呼吸窘迫综合征患者存活天数和无呼吸机天数的影响：CoDEX 随机临床试验。
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
9
Principles Guiding Nonpandemic Critical Care Research During a Pandemic.大流行期间指导非大流行危重病研究的原则。
Crit Care Med. 2020 Oct;48(10):1403-1410. doi: 10.1097/CCM.0000000000004538.
10
A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.一项回顾性对照队列研究，探讨糖皮质激素治疗对 SARS-CoV-2 感染死亡率的影响。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01168-20.